Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Insulin/GLP-1RA or Insulin/SGLT-2i vs Basal Bolus in T2D
NCT04196231Phase 4Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of insulin degludec + liraglutide, insulin glargine + lixisenatide, canagliflozin, dapagliflozin, empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University of Campania Luigi Vanvitelli. Started Nov 2019; status: completed.
02
Drugs
insulin degludec + liraglutideinsulin glargine + lixisenatidecanagliflozindapagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04196231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196231.